Chronic respiratory diseases impact the productivity and quality of life of many individuals and represent a large portion of health care spending. New approaches are needed to improve both the effectiveness and the efficiency of caring for chronically ill patients.
Improved health outcomes are possible when comprehensive and timely biological assessments are combined with tools that proactively engage patients, clinicians, and caregivers in the management of disease. ProterixBio is initially focused on delivering solutions for patients with Chronic Obstructive Pulmonary Disease (COPD).
Billerica, MA, September 29, 2020: ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay. It is being offered as a testing…
Read MoreProterixBio, Inc. will be attending Biotech Showcase™ 2019, to be held January 7-9th at the Hilton San Francisco Union Square. Biotech Showcase™, along with the Digital Medicine and Medtech…
Read More